- Home
- KMPR vs IOVA Comparison
KMPR vs IOVA Comparison
Compare KMPR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMPR
- IOVA
- Stock Information
- Founded
- KMPR 1990
- IOVA 2007
- Country
- KMPR United States
- IOVA United States
- Employees
- KMPR N/A
- IOVA N/A
- Industry
- KMPR Property-Casualty Insurers
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KMPR Finance
- IOVA Health Care
- Exchange
- KMPR Nasdaq
- IOVA Nasdaq
- Market Cap
- KMPR 3.9B
- IOVA 3.6B
- IPO Year
- KMPR N/A
- IOVA N/A
- Fundamental
- Price
- KMPR $60.69
- IOVA $10.01
- Analyst Decision
- KMPR Strong Buy
- IOVA Strong Buy
- Analyst Count
- KMPR 5
- IOVA 10
- Target Price
- KMPR $75.20
- IOVA $24.80
- AVG Volume (30 Days)
- KMPR 288.3K
- IOVA 7.0M
- Earning Date
- KMPR 10-28-2024
- IOVA 11-05-2024
- Dividend Yield
- KMPR 2.04%
- IOVA N/A
- EPS Growth
- KMPR N/A
- IOVA N/A
- EPS
- KMPR 0.80
- IOVA N/A
- Revenue
- KMPR $4,660,300,000.00
- IOVA $32,772,000.00
- Revenue This Year
- KMPR N/A
- IOVA $13,836.92
- Revenue Next Year
- KMPR $7.06
- IOVA $183.20
- P/E Ratio
- KMPR $75.81
- IOVA N/A
- Revenue Growth
- KMPR N/A
- IOVA 13669.75
- 52 Week Low
- KMPR $38.32
- IOVA $3.21
- 52 Week High
- KMPR $65.93
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- KMPR 43.52
- IOVA 46.05
- Support Level
- KMPR $62.06
- IOVA $10.32
- Resistance Level
- KMPR $63.73
- IOVA $11.80
- Average True Range (ATR)
- KMPR 1.17
- IOVA 0.60
- MACD
- KMPR -0.09
- IOVA -0.22
- Stochastic Oscillator
- KMPR 2.09
- IOVA 11.86
About KMPR Kemper Corporation
Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance. The company's property and casualty segment offers personal and commercial lines for home and automotive products. The company conducts its operations through two operating segments: Specialty Property & Casualty Insurance, and Life Insurance.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.